{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:15:40Z","timestamp":1791375340720,"version":"4.3.1"},"reference-count":14,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T00:00:00Z","timestamp":1713657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The inJectable Antiretroviral feasiBility Study (JABS) aimed to evaluate the implementation of long\u2010acting regimens in a \u2018real world\u2019 Australian setting, with inclusion of participants with complex medical needs, social vulnerability and\/or historical non\u2010adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>JABS was a 12\u2010month, single\u2010centre, single\u2010arm, open\u2010label phase IV study of long\u2010acting cabotegravir 600\u2009mg plus rilpivirine 900\u2009mg administered intramuscularly every 2 months to adults with treated HIV\u20101 infection. The primary endpoint was the proportion of attendances and administration of injections within a 14\u2010day dosing window over 12\u2009months, out of the total prescribed doses. Secondary endpoints included proportions of missed appointments, use of oral bridging, discontinuations, virological failures, adverse events and participant\u2010reported outcomes. A multidisciplinary adherence programme embedded in the clinical service known as REACH provided support to JABS participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 60 participants enrolled by May 2022, 60% had one or more complexity or vulnerability factors identified, including absence of social supports (50%), mental health issues, alcohol or drug use (30%) and financial hardship or instability (13%), among others. Twenty\u2010seven per cent of participants had historical non\u2010adherence to antiretroviral therapy. Out of 395 prescribed doses, 97.2% of injections were administered within correct dosing windows at clinic visits. Two courses of short\u2010term oral bridging were required. The rate of injection site reactions was 29%, the majority being grade 1\u20132. There were no virological failures, no serious adverse events and only one injection\u2010related study discontinuation. High baseline treatment satisfaction and acceptability of injections increased by month 12. Those with vulnerability factors had similar adherence to injections as those without such factors. Ninety\u2010eight per cent of the participants who completed 12\u2009months on the study have maintained long\u2010acting therapy, virological suppression and retention in care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long\u2010acting cabotegravir plus rilpivirine was associated with very high adherence, maintenance of virological suppression, safety and treatment satisfaction in a diverse Australian clinic population, comparable to results of phase III randomized clinical trials. Individuals with vulnerability factors can achieve adherence to injections with individualized support. Long\u2010acting therapies in this group can increase the subsequent engagement in clinical care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.13647","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T23:15:35Z","timestamp":1713741335000},"page":"935-945","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Real\u2010world use of long\u2010acting cabotegravir and rilpivirine: 12\u2010month results of the inJectable Antiretroviral therapy feasiBility Study (\n                    <scp>JABS<\/scp>\n                    )"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6429-0719","authenticated-orcid":false,"given":"M.","family":"John","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology Royal Perth Hospital  Perth Western Australia Australia"},{"name":"Immunology, PathWest  Murdoch Western Australia Australia"},{"name":"Medical Genomics IIID Murdoch University  Murdoch Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Royal Perth Hospital  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Nolan","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Royal Perth Hospital  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bonnett","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Royal Perth Hospital  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Castley","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Royal Perth Hospital  Perth Western Australia Australia"},{"name":"Immunology, PathWest  Murdoch Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Nolan","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Royal Perth Hospital  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,21]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"CABENUVA (LA CAB plus RPV) Australian Product Information https:\/\/www.tga.gov.au\/resources\/artg\/323784"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)32666\u20100"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271\u2010021\u201000524\u20100"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26003"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1013050904635"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524\u20104733.2006.00121.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.426"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010023\u201002656\u20101"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462419868359"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26006"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac631"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:54:54Z","timestamp":1726620894000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,21]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/hiv.13647"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13647","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,21]]},"assertion":[{"value":"2023-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}